For research use only. Not for use in humans.

Palivizumab (Anti-RSV-F)

Synonyms: MEDI 493 Cat.No.A2364 Purity:99%

Palivizumab (Anti-RSV-F) is a humanised monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. MW: 145.5 kD.

1 Citation

17 Nobel Prize winners
have used Selleck products

Shimon Sakaguchi

Nature Communications 2025;16, Article number:1325

David Baker

Dev Cell 2023;58(20):2163-2180.e9.

Michael Houghton

Cell Chem Biol 2020;27(7):780-792.e5

David Julius

Cell 2017;185-198.e16

Charles M. Rice

Cell 2018;172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 7.53mg/ml Endotoxin Level: ＜1EU/mg

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Palivizumab (Anti-RSV-F) is a humanised monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. MW: 145.5 kD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	188039-54-5
Molecular Weight	145.5 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.